Genetic profiling as a clinical tool in advanced parathyroid carcinoma-Reference-Cited by-同舟云学术

Genetic profiling as a clinical tool in advanced parathyroid carcinoma

Published:2019-07-15 Issue:8 Volume:145 Page:1977-1986
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Kutahyalioglu Merve,Nguyen Ha T.,Kwatampora Lily,Clarke Callisia,Silva Angelica,Ibrahim Eiman,Waguespack Steven G.,Cabanillas Maria E.,Jimenez Camilo,Hu Mimi I.,Sherman Steven I.,Kopetz Scott,Broaddus Russell,Dadu Ramona,Wanland Kacey,Williams Michelle,Zafereo Mark,Perrier Nancy,Busaidy Naifa L.^ORCID

Funder

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-019-02945-9.pdf

Reference61 articles.

1. Agha A, Carpenter R, Bhattacharya S, Edmonson SJ, Carlsen E, Monson JP (2007) Parathyroid carcinoma in multiple endocrine neoplasia type 1 (MEN1) syndrome: two case reports of an unrecognised entity. J Endocrinol Invest 30(2):145–149

2. Bihani T, Ezell SA, Ladd B, Grosskurth SE, Mazzola AM, Pietras M, Reimer C, Zinda M, Fawell S, D’Cruz CM (2015) Resistance to everolimus driven by epigenetic regulation of MYC in ER+breast cancers. Oncotarget 6(4):2407–2420

3. Burchett KM, Yan Y, Ouellette MM (2014) Telomerase inhibitor imetelstat (GRN163L) limits the lifespan of human pancreatic cancer cells. PLoS One 9(1):e85155